Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Sep-24 7:47 PM View:  | Litton Mark James President and CEO Director | Athira Pharma, Inc. (ATHA) | 05-Sep-24 | Sale | 5,032 | $0.57 | $2,848.11 | (3%) 184.09K to 179.05K | |
| 05-Sep-24 7:49 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 05-Sep-24 | Sale | 2,525 | $0.57 | $1,429.15 | (3%) 95.21K to 92.68K | |
| 05-Sep-24 7:51 PM View: | Gengos Andrew CFO AND CHIEF BUSINESS OFFICER | Athira Pharma, Inc. (ATHA) | 05-Sep-24 | Sale | 1,272 | $0.57 | $719.95 | (1%) 98.8K to 97.53K | |
| 05-Sep-24 7:50 PM View: | Lenington Rachel COO AND CDO | Athira Pharma, Inc. (ATHA) | 05-Sep-24 | Sale | 2,525 | $0.57 | $1,429.15 | (11%) 23.39K to 20.87K | |
| 05-Sep-24 7:48 PM View: | Worthington Mark General Counsel | Athira Pharma, Inc. (ATHA) | 05-Sep-24 | Sale | 2,525 | $0.57 | $1,429.15 | (5%) 54.45K to 51.93K | |
| 05-Sep-24 7:48 PM View: | Worthington Mark General Counsel | Athira Pharma, Inc. (ATHA) | 03-Sep-24 | Grant | 10,000 | -- | -- | 22% 44.45K to 54.45K | |
| 05-Sep-24 7:47 PM View: | Litton Mark James President and CEO Director | Athira Pharma, Inc. (ATHA) | 03-Sep-24 | Grant | 20,000 | -- | -- | 12% 164.09K to 184.09K | |
| 05-Sep-24 7:49 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 03-Sep-24 | Grant | 10,000 | -- | -- | 12% 85.21K to 95.21K | |
| 05-Sep-24 7:51 PM View: | Gengos Andrew CFO AND CHIEF BUSINESS OFFICER | Athira Pharma, Inc. (ATHA) | 03-Sep-24 | Grant | 5,000 | -- | -- | 5% 93.8K to 98.8K | |
| 05-Sep-24 7:50 PM View: | Lenington Rachel COO AND CDO | Athira Pharma, Inc. (ATHA) | 03-Sep-24 | Grant | 10,000 | -- | -- | 75% 13.39K to 23.39K | |
| 25-Jun-24 7:21 PM View: | Romano Kelly A Director | Athira Pharma, Inc. (ATHA) | 24-Jun-24 | Purchase | 27,400 | $2.42 | $66,179.20 | 51% 53.31K to 80.72K | |
| 25-Jun-24 7:21 PM View: | Romano Kelly A Director | Athira Pharma, Inc. (ATHA) | 21-Jun-24 | Private Purchase | 15,000 | $2.26 | $33,871.50 | 39% 38.31K to 53.31K | |
| 05-Sep-24 7:48 PM View: | Worthington Mark General Counsel | Athira Pharma, Inc. (ATHA) | 20-May-24 | Grant | 10,000 | $1.34 | $13,400.00 | 29% 34.45K to 44.45K | |
| 05-Sep-24 7:49 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 20-May-24 | Grant | 4,953 | $1.34 | $6,637.02 | 6% 80.26K to 85.21K | |
| 05-Sep-24 7:51 PM View: | Gengos Andrew CFO AND CHIEF BUSINESS OFFICER | Athira Pharma, Inc. (ATHA) | 20-May-24 | Grant | 10,000 | $1.34 | $13,400.00 | 12% 83.8K to 93.8K | |
| 08-Jan-24 4:35 PM View: | Lenington Rachel COO AND CDO | Athira Pharma, Inc. (ATHA) | 05-Jan-24 | Sale | 2,412 | $2.91 | $7,018.92 | (15%) 15.81K to 13.39K | |
| 08-Jan-24 4:38 PM View: | Worthington Mark General Counsel | Athira Pharma, Inc. (ATHA) | 05-Jan-24 | Sale | 2,412 | $2.91 | $7,018.92 | (7%) 36.86K to 34.45K | |
| 08-Jan-24 4:40 PM View: | Litton Mark James CEO Director | Athira Pharma, Inc. (ATHA) | 05-Jan-24 | Sale | 4,820 | $2.91 | $14,026.20 | (3%) 168.91K to 164.09K | |
| 08-Jan-24 4:35 PM View: | Lenington Rachel COO AND CDO | Athira Pharma, Inc. (ATHA) | 04-Jan-24 | Grant | 10,000 | -- | -- | 172% 5.81K to 15.81K | |
| 08-Jan-24 4:38 PM View: | Worthington Mark General Counsel | Athira Pharma, Inc. (ATHA) | 04-Jan-24 | Grant | 10,000 | -- | -- | 37% 26.86K to 36.86K | |
| 08-Jan-24 4:40 PM View: | Litton Mark James CEO Director | Athira Pharma, Inc. (ATHA) | 04-Jan-24 | Grant | 20,000 | -- | -- | 13% 148.91K to 168.91K | |
| 08-Jan-24 4:45 PM View: | Moebius Hans Chief Medical Officer | Athira Pharma, Inc. (ATHA) | 04-Jan-24 | Grant | 10,000 | -- | -- | 12% 81.48K to 91.48K | |
| 29-Dec-23 5:24 PM View: | Perceptive Advisors LLC Director 10% Owner | Athira Pharma, Inc. (ATHA) | 29-Dec-23 | Purchase | 163,954 | $2.38 | $390,211.00 | 3% 5.24M to 5.4M | |
| 29-Dec-23 5:24 PM View: | Perceptive Advisors LLC Director 10% Owner | Athira Pharma, Inc. (ATHA) | 28-Dec-23 | Purchase | 409,598 | $2.44 | $999,419.00 | 8% 4.83M to 5.24M | |
| 29-Dec-23 5:24 PM View: | Perceptive Advisors LLC Director 10% Owner | Athira Pharma, Inc. (ATHA) | 27-Dec-23 | Private Purchase | 32,134 | $2.28 | $73,265.50 | < 1% 4.8M to 4.83M | |
| 08-Jan-24 4:36 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 20-Nov-23 | Grant | 3,397 | $1.34 | $4,551.98 | 5% 69.27K to 72.67K | |
| 09-Jun-23 5:06 PM View: | Gengos Andrew See Below | Athira Pharma, Inc. (ATHA) | 07-Jun-23 | Private Purchase | 15,000 | $3.43 | $51,445.00 | 23% 65.01K to 80.01K | |
| 06-Jun-23 10:00 PM View: | Gengos Andrew See Below | Athira Pharma, Inc. (ATHA) | 05-Jun-23 | Purchase | 45,000 | $3.00 | $135,150.00 | 225% 20.01K to 65.01K | |
| 06-Jun-23 10:00 PM View: | Moebius Hans Chief Medical Officer | Athira Pharma, Inc. (ATHA) | 02-Jun-23 | Option Exercise | 7,882 | $1.35 | $10,640.70 | 11% 73.6K to 81.48K | |
| 06-Jun-23 10:00 PM View: | Gengos Andrew See Below | Athira Pharma, Inc. (ATHA) | 02-Jun-23 | Private Purchase | 20,012 | $2.82 | $56,422.20 | 100% 0 to 20.01K | |
| 08-Jan-24 4:38 PM View: | Worthington Mark General Counsel | Athira Pharma, Inc. (ATHA) | 18-May-23 | Grant | 7,767 | $2.41 | $18,718.50 | 41% 19.1K to 26.86K | |
| 08-Jan-24 4:36 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 18-May-23 | Grant | 809 | $2.41 | $1,949.69 | 1% 68.46K to 69.27K | |
| 06-Jun-23 10:00 PM View: | Moebius Hans Chief Medical Officer | Athira Pharma, Inc. (ATHA) | 18-May-23 | Grant | 7,764 | $2.41 | $18,711.20 | 12% 65.84K to 73.6K | |
| 31-Mar-23 4:36 PM View: | Pickering Grant Director | Athira Pharma, Inc. (ATHA) | 30-Mar-23 | Purchase | 15,000 | $2.47 | $37,050.00 | 139% 10.78K to 25.78K | |
| 30-Mar-23 6:59 PM View: | Johnson James Algot Director | Athira Pharma, Inc. (ATHA) | 29-Mar-23 | Private Purchase | 5,000 | $2.40 | $12,000.00 | 100% 0 to 5.0K | |
| 31-Mar-23 4:36 PM View: | Pickering Grant Director | Athira Pharma, Inc. (ATHA) | 29-Mar-23 | Private Purchase | 10,000 | $2.33 | $23,300.00 | 1277% 0.78K to 10.78K | |
| 27-Mar-23 4:57 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 24-Mar-23 | Option Exercise | 6,410 | $1.35 | $8,653.50 | 10% 62.05K to 68.46K | |
| 08-Jan-24 4:42 PM View: | Gengos Andrew See Below | Athira Pharma, Inc. (ATHA) | 05-Jan-23 | Sale | 1,208 | $2.91 | $3,515.28 | (1%) 85.01K to 83.8K | |
| 08-Jan-24 4:36 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 05-Jan-23 | Sale | 2,412 | $2.91 | $7,018.92 | (3%) 82.67K to 80.26K | |
| 08-Jan-24 4:36 PM View: | Church Kevin Chief Scientific Officer | Athira Pharma, Inc. (ATHA) | 04-Jan-23 | Grant | 10,000 | -- | -- | 14% 72.67K to 82.67K | |
| 08-Jan-24 4:42 PM View: | Gengos Andrew See Below | Athira Pharma, Inc. (ATHA) | 04-Jan-23 | Grant | 5,000 | -- | -- | 6% 80.01K to 85.01K | |
| 30-Dec-22 4:58 PM View: | Mileson Glenna Chief Financial Officer | Athira Pharma, Inc. (ATHA) | 28-Dec-22 | Purchase | 50,000 | $2.85 | $142,250.00 | 45% 109.93K to 159.93K | |
| 06-Dec-22 8:31 PM View: | Romano Kelly A Director | Athira Pharma, Inc. (ATHA) | 02-Dec-22 | Private Purchase | 30,000 | $3.29 | $98,700.00 | 361% 8.31K to 38.31K | |
| 31-Jan-23 7:33 PM View: | Litton Mark James Chief Executive Officer Director | Athira Pharma, Inc. (ATHA) | 18-Nov-22 | Grant | 662 | $2.74 | $1,813.88 | < 1% 148.24K to 148.91K | |
| 23-Jan-23 5:26 PM View: | Church Kevin Executive VP, Research | Athira Pharma, Inc. (ATHA) | 18-Nov-22 | Grant | 657 | $2.74 | $1,800.18 | 1% 61.4K to 62.05K | |
| 30-Dec-22 4:58 PM View: | Mileson Glenna Chief Financial Officer | Athira Pharma, Inc. (ATHA) | 18-Nov-22 | Grant | 763 | $2.74 | $2,090.62 | < 1% 109.17K to 109.93K | |
| 17-Nov-22 7:10 PM View: | Moebius Hans Chief Medical Officer | Athira Pharma, Inc. (ATHA) | 15-Nov-22 | Private Purchase | 5,000 | $3.29 | $16,442.00 | 8% 60.84K to 65.84K | |
| 31-Oct-22 8:17 PM View: | Church Kevin Executive VP, Research | Athira Pharma, Inc. (ATHA) | 28-Oct-22 | Option Exercise | 3,700 | $1.35 | $4,995.00 | 6% 57.7K to 61.4K | |
| 17-Oct-22 6:06 PM View: | Moebius Hans Chief Medical Officer | Athira Pharma, Inc. (ATHA) | 13-Oct-22 | Option Exercise | 7,881 | $1.35 | $10,639.40 | 15% 52.95K to 60.84K | |
| 01-Jul-22 2:24 PM View: | Perceptive Advisors LLC Director 10% Owner | Athira Pharma, Inc. (ATHA) | 30-Jun-22 | Purchase | 1,101,360 | $2.99 | $3,293,070.00 | 30% 3.7M to 4.8M |
